David Miller, MD
Gynecologic Oncology · Dallas, TXNPI 1568429934
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $78,044 of the $101,437 with a category attached, or 76.9%. 25 manufacturers reported payments, led by GSK at 27.7% of the total. Reporting peaked in 2019 at $24,557 and has fallen 83.5% since, to $4,057 in 2025. Among gynecologic oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $465.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$28K
- Tesaro, Inc.$19K
- Merck$14K
- Eisai Inc.$12K
- AstraZeneca$6K
- Eisai CO., LTD.$6K
- plus $16K from 19 others
Across 450 payments — averaging $4162.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.2M
- Karyopharm Therapeutics Inc.$327K
- Pfizer$114K
- Incyte Corporation$91K
- Ascendis Pharma Endocrinology Inc$42K
- EMD Serono, Inc.$34K
- plus $99K from 7 others
What the payments were for
- Consulting fees$78,04477%
- Speaking & faculty fees$5,5455%
- Travel & lodging$6,3966%
- Food & beverage$10,94811%
- Education$5040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 42 | $28,111 |
| Tesaro, Inc. | 47 | $18,618 |
| Merck | 24 | $14,040 |
| Eisai Inc. | 20 | $12,217 |
| AstraZeneca | 20 | $6,375 |
| Eisai CO., LTD. | 2 | $5,775 |
| Myriad Genetic Laboratories, Inc. | 5 | $3,275 |
| Aadi Bioscience, Inc. | 2 | $2,709 |
| Novartis | 1 | $2,167 |
| Stryker | 3 | $1,353 |
| Karyopharm Therapeutics Inc. | 3 | $1,317 |
| Genmab U.S., Inc. | 11 | $888 |
| Clovis Oncology, Inc. | 12 | $822 |
| AbbVie | 3 | $771 |
| Merck Kgaa | 1 | $690 |
| Seagen Inc. | 5 | $490 |
| Biom'up France SAS | 4 | $441 |
| Genentech USA, Inc. | 5 | $434 |
| Medical Device Business Services, Inc. | 1 | $325 |
| Immunogen, Inc. | 2 | $226 |
| Novocure Inc. | 1 | $128 |
| Boston Scientific | 1 | $112 |
| Pacira Pharmaceuticals Incorporated | 1 | $101 |
| Galvanize Therapeutics, Inc | 1 | $34 |
| Tanabe Pharma America, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$21,863
- ZEJULA$17,032
- JEMPERLI$14,912
- LYNPARZA$5,171
- myChoice CDx$3,150
- KEYTRUDA$2,389
- KISQALI$2,167
- XPOVIO$1,317
- SPY-PHI SYSTEM$712
- TIVDAK$660
- 1588 HD 3 CHIP CAMERA$641
- Rubraca$627
- HemoBlast Bellows$419
- Elahere$342
- Avastin$272
- Enhertu$121
- myRisk$113
- CLINICAL TRIAL PRODUCT$112
- EXPAREL$101
How this compares
$101,437 in reported general payments places this provider in the 90th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 12 | $9,013 |
| Megestrol Acetate | 11 | $1,162 |
| Estradiol | 16 | $1,158 |
| Dexamethasone | 17 | $402 |
| Oxycodone Hcl | 21 | $401 |
| Letrozole | 12 | $206 |
| Ondansetron Hcl | 17 | $169 |
| Prochlorperazine Maleate | 19 | $164 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Dallas
- Dustin MandersDallas$171K
- Thomas HeffernanDallas$95K
- Jayanthi LeaDallas$12K
- Jonathan OhDallas$7K
- Jessica GillenDallas$6K
- Brandon RoaneDallas$4K
- Bruce FineDallas$4K
- Laura DivineDallas$4K
- Erik KoonDallas$4K
- Alan MunozDallas$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.